Drug intelligence / Profile preview

ATX2417

Development stage: Phase 1
Lead developer: Chiesi
Modality: Small Molecules
Administration: Oral

Overview

ATX2417 is an oral small molecule drug developed as a CRTH2 (chemoattractant receptor-homologous molecule expressed on Th2 cells) antagonist. It was initially developed by Atopix Therapeutics for the treatment of Th2-mediated disorders such as asthma and atopic dermatitis. The drug acts by blocking the CRTH2 receptor, thereby reducing eosinophilic airway inflammation—a key driver in chronic respiratory diseases like asthma. ATX2417 has completed Phase 1 human safety studies and is considered a back-up candidate to OC459, another CRTH2 antagonist from the same developer.

Targets

PTGDR2 (Prostaglandin D2 receptor 2)

Beyond the preview

Go deeper on ATX2417.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATX2417.

Explore the full profile